The litigation, pending in the Northern District of California, centers on claims that the telehealth provider misled consumers and shareholders alike. On July 29, 2026, the Federal Trade Commission initiated legal action, accusing the company of sharing sensitive medical information with third-party advertisers while publicly touting stringent privacy protections. Furthermore, regulators highlighted discrepancies in the company's billing practices, noting that users were charged for prescriptions before completing mandatory consultations with medical providers.
Investors Face November Deadline in Hims & Hers Securities Lawsuit
A 14.73% single-day stock plunge has triggered a securities class action against Hims & Hers Health, Inc. following federal allegations of deceptive billing and unauthorized data sharing. Investors who acquired shares between August 2025 and July 2026 now have until November 2, 2026, to seek lead plaintiff status in the case.
Investors witnessed the immediate financial fallout when share prices dropped $4.32 to close at $25.00 on the day of the FTC announcement. Kahn Swick & Foti, LLC, the firm representing the class, is currently coordinating with those who sustained substantial losses during the period in question. Interested parties may reach out to managing partner Lewis Kahn to discuss their legal standing or the petition process for the case, Velanki v. Hims & Hers Health, Inc. et al.
Comments (0)
No comments yet. Be the first!